Morningstar

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Business Wire

Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and ...
Newswire

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell ...

TORONTO, Jan. 27, 2026 /CNW/ - Eli Lilly Canada, Inc announced today that Jaypirca ® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available for use as monotherapy for the treatment of ...
Business Wire

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and ...
Seeking Alpha

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...